Get started

Ichimoku_trader

COVID19 AND THE VIX -- daily Ichimoku cloud breaksin the recent past, when we see a Ichimoku Cloud break in the VIX ( Volatility S&P 500 Index ) we see a strong acceleration upwards. The most recent example of this was on 13 Feb 2020 Inversely proportional to the VIX , the S&P 500 Index had a significant breakdown, represented on 21 Feb 2020 Since COVID19 outbreak, governments around the world have been scrambling to control their domestic economies by stimulus and monetisation of debt stoking Global Hyperinflation, and now real people are starting to feel the economic effects of Lockdowns and COVID19 travel and border restrictions. Currently TVC:SPX is entering the cloud, and the VIX is coiling to break through the cloud. This is true for other Major Indices around the world. Northern Hemisphere is entering their "winter flu season" and USA has their contentious Presidential Election looming in NOV. This could be shaping up for a BIG BOUT of VOLATILITY....
TVC:VIXLong
by Outside_The_Box_NZ
$4672.50 in 2006 to $6.00 - Huge Demand, Robust EarningsPacific Ethanol, Inc. produces and markets low-carbon renewable fuels and alcohol products in the United States. The company operates in two segments, Production and Marketing. It produces and markets ethanol; and co-products, such as wet and dry distillers grains, wet and dry corn gluten feed, condensed distillers solubles, corn gluten meal, corn germ, corn oil, dried yeast, and CO2, as well as markets ethanol produced by third parties. The company also offers ethanol transportation, storage, and delivery services through third-party service providers. It sells ethanol to integrated oil companies and gasoline marketers; distillers grains and other feed co-products to dairies and feedlots; and corn oil to poultry and biodiesel customers. The company owns and operates nine ethanol production facilities, including four plants located in the Western states of California, Oregon, and Idaho; and five plants in the Midwestern states of Illinois and Nebraska. Pacific Ethanol, Inc. was founded in 2003 and is headquartered in Sacramento, California. I think this is the beginning of something huge. As I noted, the stock hit a high of $4672.50 in 2006. Demand for Alcohol products in the United States and around the World is outstripping supply as can be seen in Pacific Ethanol's last earnings report below. The company continues to pay down its debt too. August 11, 2020 Shares of Pacific Ethanol (NASDAQ:PEIX) moved higher by 38.29% in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share rose 258.82% over the past year to $0.27, which beat the estimate of ($0.20). Revenue of $212,074,000 beat the estimate of $174,200,000. This is a pure turnaround play in my opinion with a lot of room to run a lot higher. Daily Chart is Bullish with most indicators trending up, Bullish The stock continues to make new 52-week highs. Long! DISCLAIMER The Content herein is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice.
PLong
by HotCharts
XAUUSD, 4hr tf, sell on triangle breakout with ichimoku updatedHello my friends, Today is such a good day for me. I posted about selling XAUSD on September 4th from 1937, price took my sell order and today it was closed in profit This XAUUSD sell position which i took on September 4th closed with +280 pips profit banking +4% profit as i used 2% risk only. Price go down to 1908 area and then get rejected aggresively. That 1908 area is where exactly our take profit placed. Congratultions to everyone following this sell call from me. Follow me and give me thumbs up if you enjoy my call. Also stay tuned for my next post.
OANDA:XAUUSDShort
by HayatoDragonFX
3
GBPCHF, daily tf, bulls in control after 3 weeks consolidationHello my friends, Here is a good setup for GBPCHF pairs, price has failed to closed above 1.2030 resitance since August 3rd. The first time GBPCHF reach it, they got rejected and price then consolidating for 3 weeks. Finally the Friday candle closed above it and i think GBPCHF ready to go higher from this point There is a chance during Monday, price could go down to retest 1.2030 as a support, this will be our cue to buy GBPCHF on the retest. I am gonna buy GBPCHF if it come to retest it on Monday. The nearest resistance is at 1.2200 area, after price breaking above this area it could be a highway until 1.24500 Buy GBPCHF 1.2030 Stop loss 1.1890 Take profit 1 @1.2200 Take profit 2 @1.2450 RR ratio 1:3 Good luck
Long
by HayatoDragonFX
USDJPY, daily tf, potential shoulders head pattern below kumo(2)Hello everyone, I am updating my recent USDJPY position taken at 106.40. I took my first sell position at 25th August 2020 and price just start going my way at Friday. It first went against my position but luckily it never hit my SL so i am still safe. I've taken partial profit as price hit 105.40 which is +100 pips profit. Stop loss already moved to entry and now i will hold this pair for next TP at 104.00 I am actually quite interested to add more sell position but tomorrow will be monthly candle closing so i will hold it until September. Good luck to those who sell USDJPY with me
Short
by HayatoDragonFX
GBPCAD Possible LongPossible Golden TK Cross on daily timeframe may send this pair flying. My entry point was a bit risky due to the bearish cross on the daily but this pair found some good support off the weekly level (touched TK on the weekly and bounced right up). Given that, I found a good entry point on the 4hr timeframe that allowed me to have great RR ratio. The momentum of the bounce has this price almost ready for a golden cross. If we follow the momentum on this pair, the golden cross on the daily timeframe may yield a bullish golden cross on the weekly level pushing this pair to higher levels. If this occurs, the weekly levels of .8400 could be possible. This would coincide with the monthly bullish cross, retest of both Kijun Sen and Tenkan Sen to the upside. Entry: .73586 Stop: .7300 TP1: .76450 TP2: Open
Long
by aldairhernandez30
Bullish Charts - Online Learning in ChinaRYB Education, Inc. provides early childhood education service in the People's Republic of China. The company offers kindergarten services to 2-6-year-old children; and play-and-learn centers services for the joint participation of 0-6-year-old children and their adult family members to promote children's development, foster bonding with family, and prepare them for their entry into kindergartens and primary schools. It also develops and sells educational products and services, such as teaching aids, educational toys, at-home educational products, and school uniforms through franchisees and other business partners, as well as directly to a market of families. As of December 31, 2019, it operated 100 directly operated and 250 franchise kindergartens; and 6 play-and-learn centers. The company was formerly known as Top Margin Limited and changed its name to RYB Education, Inc. in June 2017. RYB Education, Inc. was founded in 1998 and is based in Beijing, China. Daily Chart is Bullish Broke out above the cloud yesterday. Indicators are Bullish Long DISCLAIMER The Content herein is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice.
RLong
by HotCharts
2
Disposable Surgical Robotic Device - BIG News Coming 8/17/20Microbot Medical Inc., a pre-clinical medical device company, researches, designs, and develops micro-robotics assisted medical technologies targeting the minimally invasive surgery space. The company, through its ViRob, TipCAT, and Liberty micro-robotic technologies, developing Self Cleaning Shunt for the treatment of hydrocephalus and normal pressure hydrocephalus; a disposable self-propelled locomotive device to treat capabilities within tubular lumens, such as the blood vessels, respiratory, and the urinary and GI tracts; a combination of a guidewire and microcatheter technologies that are used for endoluminal surgery; and maneuver guidewire, microcatheters, and over-the-wire devices within the body's vasculature. It has 37 issued/allowed patents and 15 patent applications pending worldwide. Microbot Medical Inc. was founded in 2010 and is based in Hingham, Massachusetts. Microbot Medical to Share Current Results of a Feasibility Animal Study Utilizing the LIBERTY Robotic System Results to be shared on August 17th during Needham’s Virtual Med Tech & Diagnostics Conference HINGHAM, Mass., Aug. 13, 2020 (GLOBE NEWSWIRE) -- At the upcoming Needham Virtual Med Tech & Diagnostics Conference, being held on Monday, August 17, 2020, Microbot Medical Inc. (Nasdaq: MBOT), will provide initial results of a feasibility animal study performed using the Company’s LIBERTY Robotic System. finance.yahoo.com On 1/13/20, H.C. Wainwright maintained a Buy rating on MBOT and raised the price target from $12 to $26.00. I think this device could be a game changer. Disposable medical devices is where the future is going especially for sanitary reasons. Watch this stock Monday, 8/17/2020, it could run hard. I think the stock has been consolidating for a while and is coiling and ready to explode higher. Long! DISCLAIMER The Content herein is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice.
NASDAQ:MBOTLong
by HotCharts
Beat Earnings. Raised Guidance. No Debt. USA Protective GearAlpha Pro Tech, Ltd., together with its subsidiaries, engages in developing, manufacturing, and marketing a line of disposable protective apparel and infection control, and building supply products in the United States and internationally. The company operates through two segments, Building Supply and Disposable Protective Apparel. The Building Supply segment offers construction weatherization products, such as house wrap, synthetic roof underlayment, and other woven materials. The Disposable Protective Apparel segment provides shoecovers, bouffant caps, gowns, coveralls, lab coats, hoods, and frocks, as well as face masks and face shields. The company provides its products under the Alpha Pro Tech brand name, as well as under private labels. Its products are used primarily in cleanrooms; industrial safety manufacturing environments; health care facilities, such as hospitals, laboratories, and dental offices; pharmaceutical markets; and building and re-roofing sites. The company distributes its products through a network of purchasing groups, distributors, and independent sales representatives, as well as through its sales and marketing force. Alpha Pro Tech, Ltd. was founded in 1983 and is headquartered in Markham, Canada. Net Sales of $25.5 Million, an Increase of 123.4% Year-over-Year Provides Update on Orders for Personal Protective Equipment (PPE) Net sales for the second quarter of 2020 were $25.5 million, compared to $11.4 million for the second quarter of 2019, up 123.4% year-over-year. Net income for the second quarter of 2020 was $6.2 million, or $0.46 per diluted share, compared to $1.0 million, or $0.08 per diluted share, for the second quarter of 2019, up 475% on a per share basis. NOGALES, Ariz., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Alpha Pro Tech, Ltd. (NYSE American: APT), a leading manufacturer of products designed to protect people, products and environments, including disposable protective apparel and building products, today announced financial results for the three month period ended June 30, 2020. finance.yahoo.com Need I say anymore? Earnings blew past Wall Street Estimates. APT raised guidance and the company has no debt. Protective gear and N95 masks will be a part of the Worldwide dress code through 2020 and into 2021 even if a vaccine is approved because not everyone will want to take the vaccine shot. Today's sell off was outrageous and an early Christmas gift for anyone looking for a quality company that makes protective gear & N95 masks in the USA! Target: $32 Long! DISCLAIMER The Content herein is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice.
AMEX:APTLong
by HotCharts
2
Bullish Charts - Huge Earrings BeatDURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and pharmaceutical programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for experimental research in mice, rats, and other laboratory animals; and a range of biodegradable polymers for pharmaceutical and medical device clients for use as raw materials in their products under the LACTEL brand. Its product pipeline consists of multiple investigational drug candidates in development, such as DUR-928, an endogenous, orally bioavailable small molecule that is in Phase I and II development stage to play a regulatory role in lipid homeostasis, inflammation, and cell survival. The company's oral and injectable delivery technologies are designed to enable new indications and enhanced attributes for small-molecule and biologic drugs, including POSIMIR, an investigational analgesic product intended to deliver bupivacaine to provide up to 3 days of pain relief after surgery. DURECT Corporation markets and sells its ALZET and LACTEL product lines through direct sales force in the United States, as well as through a network of distributors in Japan, Europe, and internationally. The company has strategic collaboration and other agreements with Virginia Commonwealth University Intellectual Property Foundation; Indivior UK Ltd.; Santen Pharmaceutical Co., Ltd.; Sandoz AG; and Zogenix, Inc. DURECT Corporation was founded in 1998 and is headquartered in Cupertino, California. This morning Durect reported earrings that blew away Wall Street Estimates. Q2 EPS $0.07 Up From $(0.04) YoY, Sales $25 Million Beat $11.48 Million Estimate Sales more than doubled estimates. Daily Chart is Bullish Indicators are rising, Bullish Long! DISCLAIMER The Content herein is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice.
NASDAQ:DRRXLong
by HotCharts
Rapid Recovery Respiratory Failure - COVID-19 TreatmentRelief Therapeutics Holding AG, a clinical stage biotechnology company, engages in developing treatment solutions for indications related to diabetic complications and respiratory diseases. The company is developing aviptadil, which has completed Phase II clinical trial for the treatment of sarcoidosis, an orphan pulmonary disease, as well as pulmonary hypertension; and atexakin alfa that has completed Phase I clinical trial to treat peripheral diabetic neuropathy. Relief Therapeutics Holding AG is based in Geneva, Switzerland. RLF-100 (aviptadil) clinical trial showed rapid recovery from respiratory failure and inhibition of coronavirus replication in human lung cells - Rapid recovery of patients on ventilators and ECMO (extracorporeal membrane oxygenation) was seen in patients with severe medical comorbidities after three days of treatment with RLF-100 under FDA Emergency Use IND authorization at multiple clinical sites - Aviptadil is being developed as the first COVID therapeutic to block replication of the SARS-CoV-2 virus in human lung cells and monocytes - RLF-100 is a patented formulation of aviptadil (synthetic human Vasoactive Intestinal Polypeptide VIP), which has been granted FDA Fast Track Designation, FDA emergency use IND authorization, and an expanded access protocol finance.yahoo.com I think this stock could spike like Moderna Long! DISCLAIMER The Content herein is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice.
OTC:RLFTFLong
by HotCharts
1
Bullish Charts - Plasma Play, FDA Approved Plasma FacilitiesADMA Biologics, Inc., a biopharmaceutical and specialty immunoglobulin company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States. It offers BIVIGAM, an intravenous immune globulin product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB, which is indicated for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It also develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, the company operates source plasma collection facilities. The company distributes its products through independent distributors, sales agents, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was founded in 2004 and is headquartered in Ramsey, New Jersey. BREAKING NEWS TODAY - 07/30/2020 ADMA Biologics shares are trading higher following a report suggesting the company is near receiving emergency use authorization of Convalescent Plasma in COVID-19 patients. www.benzinga.com On July 6, 20, ADMA opened a new plasma facility and is awaiting emergency authorization for a second location. finance.yahoo.com With the FDA asking for everyone to donate plasma, this stock could rip! Plasma stocks ripped today and continue to rip. This company already is up and running one plasma facility. Game On! Long DISCLAIMER The Content herein is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice.
NASDAQ:ADMALong
by HotCharts
WFC - 1H - 21.07.2020 (17.07 Follow up)#WFC -1H - 21.07.2020 - Ready, set... After a brief skid this monday, price broke our second downtrend with a solid bullish candel (Economic fundamental causes behind it). Hopefully, the beginning of new tendence. If we look at closely our Ichimoku cloud indicator, we will find that tenkan (convertion line) crosses upward Kijun (base line) when the price is above the cloud. According to the rule book of our friend Mr. Ichimoku, this is equivalent to a strong buy signal entry. Tomorrow will be crucial to consolidate a 25.90 - 26.10 price range. After that, we can start thinking about the firt medium term resistance at 30 USD.
NYSE:WFCLong
by aoberninger
2
Bullish Charts - FDA Grants Orphan Drug Designation for LymphomaMiragen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing proprietary RNA-targeted therapies with a specific focus on microRNAs and their role in diseases where there is a high-unmet medical need. Its four lead product candidates include cobomarsen, an inhibitor of miR-155 for treating various blood cancers, such as cutaneous T-cell lymphoma, adult T-cell lymphoma/leukemia, diffuse large B-cell lymphoma, and chronic lymphocytic leukemia; Remlarsen, a replacement for miR-29, a microRNA that is found at abnormally low levels in various pathological fibrotic conditions, including cutaneous and ocular fibrosis, which is in Phase II clinical trial; MRG-229, which is in preclinical trial for the treatment of idiopathic pulmonary fibrosis; and MRG- 110, an inhibitor of miR-92, a microRNA expressed in endothelial cells, which has completed two Phase I clinical trial for the treatment of heart failure, wound healing, and other ischemic disease in the United States and Japan. Miragen Therapeutics, Inc. was founded in 2006 and is based in Boulder, Colorado. LATE BREAKING NEWS AFTER HOURS - POSSIBLY A BIG SPIKE IN THE MORNING miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced that the Food & Drug Administration (FDA) has granted orphan drug designation to cobomarsen, for the treatment of T-cell lymphoma. DAILY CHART IS BULLISH OBV is Bullish MACD turned up Bullish RSi crossed center line and turned up, Bullish PMO is turning up, Bullish This little stock could spike hard. Best of luck everyone! DISCLAIMER The Content herein is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice.
MLong
by HotCharts
Bullish Charts - Vaccine Reduced COVID-19 into Common ColdAbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the United States, Japan, Germany, Canada, France, Spain, Italy, the Netherlands, the United Kingdom, Brazil, and internationally. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; VIEKIRA PAK, an interferon-free therapy to treat adults with genotype 1 chronic hepatitis C virus (HCV); TECHNIVIE to treat adults with genotype 4 HCV infection; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides SYNAGIS that protects at-risk infants from severe respiratory disease; KALETRA, a prescription anti-HIV-1 medicine; CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; and Lupron, a product for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; and Sevoflurane, an anesthesia product. It has collaborations with Calico Life Sciences LLC; Alector, Inc.; Janssen Biotech, Inc.; Jacobio Pharmaceuticals; and Genmab A/S. The company was incorporated in 2012 and is based in North Chicago, Illinois. On 07/15/20, Researchers said AbbVie's Tricor reduced severity of COVID-19 into "NOTHING WORSE THAN A COLD." www.yahoo.com In my opinion, a vaccine doesn't get any better than this. AbbVie has the vaccine! Where is all the great news about Tricor killing COVID-19.??? If the stock can break through around $107, I think it's going to spike hard! The daily chart looks great. Long! DISCLAIMER The Content herein is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice.
NYSE:ABBVLong
by HotCharts
Bullish Charts - Robust Earnings, Electric Vehicle TechnologiesGarrett Motion Inc. designs, manufactures, and sells turbocharger and electric boosting technologies for light and commercial vehicle original equipment manufacturers and the aftermarket worldwide. The company offers light vehicle gasoline and diesel, and commercial vehicle turbochargers. Its integrated vehicle health management tools detect intermittent faults and anomalies to provide understanding of the real-time health of a vehicle system. The company offers its products through distribution networks. Garrett Motion Inc. was incorporated in 2018 and is headquartered in Rolle, Switzerland. Daily Chart looks great! Volume, Bullish PMO, Bullish MACD, Bullish RSI, Bullish Stochastic, Bullish On Balance Trending Up, Bullish Accumulation Trending Up, Bullish It looks like the stock price broke out above the cloud at or around the $5.73 range. On 05/11/20, the company announced a huge spike in EPS. Q1 EPS $0.91, Sales $745.000 Million, Beat $664.040 Million Wall Street Estimates This one sentence sums up why the company is seeing a surge in revenue and earnings... "Garrett Motion Inc. designs, manufactures, and sells turbocharger and electric boosting technologies for light and commercial vehicle original equipment manufacturers and the aftermarket worldwide. " The electric vehicle industry is red hot! Long! DISCLAIMER The Content herein is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice.
GLong
by HotCharts
Bullish Charts - COVID-19 VaccineGilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases. It also provides Yescarta, a chimeric antigen receptor T cell therapy for adult patients with relapsed or refractory large B-cell lymphoma; Zydelig, a kinase inhibitor; Letairis, an oral formulation of an endothelin receptor antagonist for pulmonary arterial hypertension; Ranexa, a tablet to treat chronic angina; and AmBisome, an antifungal agent to treat serious invasive fungal infections. In addition, the company offers its products under the name Cayston, Emtriva, Hepsera, Sovaldi, and Tybost. Further, it develops product candidates for the treatment of viral diseases, inflammatory and fibrotic diseases, and oncology. The company markets its products through its commercial teams; and in conjunction with third-party distributors and corporate partners. Gilead Sciences, Inc. has collaboration agreements with Bristol-Myers Squibb Company; Janssen Sciences Ireland UC; Japan Tobacco Inc.; Galapagos NV; Second Genome; Gadeta; Carna Biosciences Inc.; Nurix Therapeutics, Inc.; Humanigen, Inc.; Kiniksa Pharmaceuticals, Ltd.; Kyverna Therapeutics, Inc.; Glympse Bio, Inc.; Renown Institute for Health Innovation; Goldfinch Bio, Inc.; Insitro, Inc.; Novo Nordisk A/S; Yuhan Corporation; Kite Pharma, Inc.; oNKo-innate Pty. Ltd.; and Roche Holding AG. The company has partnership with Arcus Biosciences, Inc. to co-develop and co-commercialize next-generation cancer immunotherapies. Gilead Sciences, Inc. was founded in 1987 and is headquartered in Foster City, California. On 07/11/20, Gilead announced its drug Remdesivir can reduce risk of death in COVID-19 patients. On 07/10/20, Former FDA Commissioner Scott Gottlieb said Remdesivir data showed improved COVID-19 Recovery & Reduced Risk of Death by 62%. The COVID-19 drug alone could be a huge revenue boom for Gilead into the future as many countries stockpile & use it. On the Daily Chart, it looks to me like a Pennant has formed with a breakout coming, Bullish Volume, Bullish PMO, Bullish MACD, Bullish RSI, Bullish OBV, Bullish Long! DISCLAIMER The Content herein is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice.
NASDAQ:GILDLong
by HotCharts
1
Bullish Industry - Protective Gear, N95 Masks, Robust EarningsAlpha Pro Tech, Ltd., together with its subsidiaries, engages in developing, manufacturing, and marketing a line of disposable protective apparel and infection control, and building supply products in the United States and internationally. The company operates through two segments, Building Supply and Disposable Protective Apparel. The Building Supply segment offers construction weatherization products, such as house wrap, synthetic roof underlayment, and other woven materials. The Disposable Protective Apparel segment provides shoecovers, bouffant caps, gowns, coveralls, lab coats, hoods, and frocks, as well as face masks and face shields. The company provides its products under the Alpha Pro Tech brand name, as well as under private labels. Its products are used primarily in cleanrooms; industrial safety manufacturing environments; health care facilities, such as hospitals, laboratories, and dental offices; pharmaceutical markets; and building and re-roofing sites. The company distributes its products through a network of purchasing groups, distributors, and independent sales representatives, as well as through its sales and marketing force. Alpha Pro Tech, Ltd. was founded in 1983 and is headquartered in Markham, Canada. On 06/25/20, Alpha Pro announced it will join the Russell 2000 and Russell 3000 Indexes. The company is also currently included in the Russell Microcap Index. On 06/23/20, Business Wire announced Aplha Pro serves a $15 Billion dollar Worldwide industry. On 05/06/20, Alpha Pro announced ROBUST earnings that blew away Wall Street estimates. Q1 EPS $0.39 up from $0.09 YoY. In addition, Alpha Pro had 16% growth in its Building Supply segment. The company has experienced a SURGE in customer demand for its "Proprietary" N-95 Particulate Respirator face mask and other PPE products as a result of the pandemic. As of May 1, 2020, the company has approx. $46.8 million in orders for the N-95 mask alone. Alpha Pro has also experienced a robust demand for its "Face Shield" products with orders totaling $13.3 Million as of May 1, 2020. Alpha Pro ended the 1st qtr of 2020 with working capital of $31.6 million and a current ration of a solid 4:1 - (Bullish Ratio - Strong Cash Position) The company currently has NO OUTSTANDING DEBT and an unused $3.5 million credit line. With the recent uptick in COVID-19 infections, more and more states are requiring masks for all activities especially for frontline employees. The need for Alpha Pro products is not going away anytime soon. Rapid Growth should continue far into 2021 and beyond. Long! DISCLAIMER The Content herein is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice.
AMEX:APTLong
by HotCharts